NCT07601763Recruiting
Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)
Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life. Catheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life. Pulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve. This trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1574 (estimated)
- First submitted
- 8 May 2025
- Start date
- Apr 2025
- Primary completion date
- Nov 2027
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Atrial fibrillation
- NCT number
- NCT07601763
What you commit to
- Study type: Interventional
- Planned participants: 1574
- From Apr 2025 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participate in clinical trials related to other drugs or devices.
Other illness
- Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)
- Myocardial infarction, or any cardiac interventional/surgery has been performed within 3 months.
- Had a stroke or transient ischemic attack within 6 months.
- Allergy to iodine contrast agents.
- Active stage of infection.
- Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.
Other
- Have accepted catheter ablation before.
- Pregnant women, lactating women, or women with plans to become pregnant shortly.
- Patients who do not agree to be enrolled or are unable to cooperate to complete the study
Who the study is looking for
- Atrial fibrillation patients who will accept catheter ablation.
- Age ≥ 18.
- Be capable of understanding and signing the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cardiovascular Diseases Center, Fuwai Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.